Alzheimer’s agitation non-antipsychotic drug therapy market seen reaching $9.98 billion by 2030

The market for Alzheimer’s agitation non-antipsychotic drug therapies is projected to grow from $5.09 billion in 2025 to $9.98 billion by 2030, driven by demand for safer behavioral treatments and more R&D in neurodegenerative disease. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Alzheimer’s agitation is a major care challenge, and non-antipsychotic drugs are aimed at treating behavioral symptoms without the safety concerns tied to antipsychotic use. - The market’s projected growth signals stronger demand for safer dementia-care options as the global population ages. - The category matters for long-term care settings, where agitation can affect quality of life, caregiver burden and treatment decisions.

What happened: - The Business Research Company released its Alzheimer’s Agitation Non-Antipsychotic Drug Therapy Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report says the market will rise from $5.09 billion in 2025 to $5.85 billion in 2026. - The report projects the market will reach $9.98 billion by 2030, implying a 14.3% CAGR in the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report includes analysis across Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample and the full report are available online: Download the sample report and View the full report.

The details: - Historical growth was driven by rising Alzheimer’s prevalence, an aging global population, greater awareness of dementia-related behavioral symptoms, neurological research efforts and concern about antipsychotic side effects. - The therapies are defined as pharmacological treatments for agitation, aggression and related behavioral symptoms in Alzheimer’s patients that do not use antipsychotic medications. - These drugs are designed to modulate neurotransmitter systems and neurobiological pathways linked to mood, behavior and cognition. - The stated goal is to reduce risks associated with antipsychotics, including sedation, cognitive decline and cardiovascular complications. - Forecast growth is expected to be supported by more investment in neurodegenerative disease drug development, precision medicine demand, clinical trials of new neurobehavioral therapies, home-based dementia care and regulatory support for safer options. - Emerging trends include safer alternatives to antipsychotics, targeted symptom management, multimodal therapy strategies, research into neurotransmitter pathway modulation and more trials for central nervous system therapies. - The report cites Australia’s dementia burden, noting about 25,000 people living with dementia there in December 2025, including approximately 266,000 women and 159,000 men, or roughly 16 cases per 1,000 Australians. - The report also cites US R&D spending rising from $892 billion in 2022 to $940 billion in 2023, a gain of $48 billion.

Between the lines: - The market outlook reflects a broader shift in dementia care toward treatments that try to manage behavior while avoiding the adverse effects associated with traditional antipsychotics. - Stronger pipeline activity suggests drug developers see unmet need in a large and growing patient population. - The regional split points to a mature North American market and a faster-expanding Asia-Pacific opportunity as diagnosis and care access widen.

What’s next: - More clinical trials are expected to test novel neurobehavioral therapies and central nervous system candidates. - Investment in neurodegenerative disease research should keep expanding the therapeutic pipeline. - Home-based dementia care services may increase demand for drugs that are easier to use and safer for long-term management. - The report says stronger regulatory backing could further support adoption of safer treatment options.

The bottom line: - Alzheimer’s agitation non-antipsychotic drug therapy is moving from a niche category to a fast-growing global market built around safety, symptom control and unmet clinical need.